These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 18176961)

  • 21. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
    Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis.
    Hanai H; Takeuchi K; Iida T; Kashiwagi N; Saniabadi AR; Matsushita I; Sato Y; Kasuga N; Nakamura T
    Dig Dis Sci; 2004 Sep; 49(9):1438-43. PubMed ID: 15481316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fecal excretion of deoxyribonucleic acid in long-term follow-up of patients with inactive ulcerative colitis.
    Casellas F; Borruel N; Antolín M; Varela E; Torrejón A; Armadans L; Guarner F; Malagelada JR
    Inflamm Bowel Dis; 2007 Apr; 13(4):386-90. PubMed ID: 17206700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1.
    Reinisch W; Bressler B; Curtis R; Parikh A; Yang H; Rosario M; Røseth A; Danese S; Feagan B; Sands BE; Ginsburg P; Dassopoulos T; Lewis J; Xu J; Wyant T
    Inflamm Bowel Dis; 2019 Mar; 25(4):803-810. PubMed ID: 30295811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy.
    De Vos M; Louis EJ; Jahnsen J; Vandervoort JG; Noman M; Dewit O; Dʼhaens GR; Franchimont D; Baert FJ; Torp RA; Henriksen M; Potvin PM; Van Hootegem PP; Hindryckx PM; Moreels TG; Collard A; Karlsen LN; Kittang E; Lambrecht G; Grimstad T; Koch J; Lygren I; Coche JC; Mana F; Van Gossum A; Belaiche J; Cool MR; Fontaine F; Maisin JM; Muls V; Neuville B; Staessen DA; Van Assche GA; de Lange T; Solberg IC; Vander Cruyssen BJ; Vermeire SA
    Inflamm Bowel Dis; 2013 Sep; 19(10):2111-7. PubMed ID: 23883959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
    García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
    J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of three commercial fecal calprotectin ELISA test kits used in patients with Inflammatory Bowel Disease.
    Mirsepasi-Lauridsen HC; Bachmann Holmetoft U; Ingdam Halkjær S; Angeliki Krogfelt K; Munk Petersen A
    Scand J Gastroenterol; 2016; 51(2):211-7. PubMed ID: 26359672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The combination of fecal calprotectin with ESR, CRP and albumin discriminates more accurately children with Crohn's disease.
    Daniluk U; Daniluk J; Krasnodebska M; Lotowska JM; Sobaniec-Lotowska ME; Lebensztejn DM
    Adv Med Sci; 2019 Mar; 64(1):9-14. PubMed ID: 30237086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
    Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing the Correlation of Fecal Calprotectin and the Clinical Disease Activity Index in Patients With Ulcerative Colitis.
    Amiriani T; Besharat S; Dadjou M; Roshandel G; Mirkarimi H; Salamat F; Joshaghani H
    Gastroenterol Nurs; 2018; 41(3):201-205. PubMed ID: 29847394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis.
    Kawashima K; Ishihara S; Yuki T; Fukuba N; Oshima N; Kazumori H; Sonoyama H; Yamashita N; Tada Y; Kusunoki R; Oka A; Mishima Y; Moriyama I; Kinoshita Y
    BMC Gastroenterol; 2016 Apr; 16():47. PubMed ID: 27071448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis.
    Lee SH; Kim MJ; Chang K; Song EM; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK; Ye BD
    BMC Gastroenterol; 2017 Oct; 17(1):110. PubMed ID: 29061121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Ulcerative Colitis.
    Singh S; Ananthakrishnan AN; Nguyen NH; Cohen BL; Velayos FS; Weiss JM; Sultan S; Siddique SM; Adler J; Chachu KA;
    Gastroenterology; 2023 Mar; 164(3):344-372. PubMed ID: 36822736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis.
    Burri E; Beglinger C; von Felten S; Lehmann FS
    Dig Dis Sci; 2015 Feb; 60(2):485-91. PubMed ID: 25344905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis.
    Lasson A; Simrén M; Stotzer PO; Isaksson S; Ohman L; Strid H
    Inflamm Bowel Dis; 2013 Mar; 19(3):576-81. PubMed ID: 23377170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fecal calprotectin is more accurate than fecal immunochemical test for predicting mucosal healing in quiescent ulcerative colitis: a prospective multicenter study.
    Kim ES; Lee HS; Kim SK; Kim EY; Jang BI; Kim KO; Yang CH; Lee YJ;
    Scand J Gastroenterol; 2020 Feb; 55(2):163-168. PubMed ID: 31984815
    [No Abstract]   [Full Text] [Related]  

  • 38. Pancreatitis-associated protein has no additional value as a marker of disease activity in a real-life cohort of IBD patients.
    Bodelier AG; Pierik MJ; van den Heuvel T; Bovee-Oudenhoven IM; de Boer E; Hameeteman W; Masclee AA; Jonkers D
    Eur J Gastroenterol Hepatol; 2014 Aug; 26(8):902-9. PubMed ID: 24915490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of Common Disease Activity Markers as a Reflection of Inflammatory Burden in Ulcerative Colitis.
    Brandse JF; Bennink RJ; van Eeden S; Löwenberg M; van den Brink GR; DʼHaens GR
    Inflamm Bowel Dis; 2016 Jun; 22(6):1384-90. PubMed ID: 26978724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Fecal Calprotectin as a Noninvasive Indicator for Ulcerative Colitis Disease Activity.
    Nakov RV; Nakov VN; Gerova VA; Tankova LT
    Folia Med (Plovdiv); 2019 Jun; 61(2):188-196. PubMed ID: 31301663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.